Literature DB >> 6455513

Enzymatic assays for 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline, a promising new "nonclassical" antifolate.

J J Heusner, J J McCormack.   

Abstract

2,4-Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)-methyl]quinazoline (I) is a promising new "nonclassical" antifolate. Inhibition of dihydrofolate reductase from bacterial (Lactobacillus casei)and mammalian (beef liver) sources was employed to develop useful enzymatic assays for this compound. A linear relationship was obtained by plotting the I concentration versus 1/V. The resultant standard curves maintained linearity particularly well between the 30 and 70% control range, with a correlation coefficient of 0.99 for both enzyme systems. The two enzyme systems are characterized by differences in sensitivity, stability, and day-to-day variation. The ID50 for the beef liver reductase system was 1.6 X 10(-9) M (+/-0.03); for the L. casei system, it was 1.35 X 10(-8) M (+/- 0.2). The apparent advantage for the beef liver enzyme was offset somewhat by its relative instability and its higher day-to-day variability. Studies in mice demonstrated that these assays are suitable for pharmacokinetic studies in vivo. Such studies indicated that I has a serum t1/2 of 45 min in mice; a similar serum t1/2 (50 min) was estimated in studies with 14C-labeled I in position 6.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6455513     DOI: 10.1002/jps.2600700737

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

1.  Trimetrexate: a new antifol entering clinical trials.

Authors:  P J O'Dwyer; D D Shoemaker; J Plowman; J Cradock; A Grillo-Lopez; B Leyland-Jones
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

Review 2.  Novel antifolate drugs.

Authors:  W Thomas Purcell; David S Ettinger
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

3.  A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.

Authors:  L B Grochow; D A Noe; D S Ettinger; R C Donehower
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 4.  Biological and biochemical properties of new anticancer folate antagonists.

Authors:  D W Fry; R C Jackson
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

5.  A phase I study of trimetrexate (NSC 352122) administered by 5-day continuous intravenous infusion.

Authors:  J F Bishop; D Raghavan; I N Olver; P Reece; R Morris; M L Friedlander
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.